Contents

Request for Proposals: Bloomberg Initiative to Reduce Tobacco Use STOP (Stop Tobacco Organizations and Products) ........................................................ 2
Avatar XPRIZE ........................................................................................................ 3
Cystic Fibrosis Foundation Research Grants – Spring Cycle ........................................ 3
One Mind Rising Star Awards ..................................................................................... 4
Request for Proposals: Mouse Drug Testing Facility for Myotonic Dystrophy .......... 7
Elsa U. Pardee Foundation Research Grant Program ................................................. 8
Cystic Fibrosis Foundation Postdoctoral Research Fellowship Award ....................... 8
FSH Society Fellowship and Grants Program ............................................................ 9
Cystic Fibrosis Foundation Pilot and Feasibility Awards – Spring Cycle ................. 10
Aetna Foundation 2018 Cultivating Healthy Communities Grant Program .. 11
Culture of Select Poultry Viruses in Immortalized Cell Substrates ....................... 12
Request for Applications: Rivkin Center for Ovarian Cancer Bridge Funding Award ... 13
Science & SciLifeLab Prize for Young Scientists .................................................... 14
TEVA Challenge: Novel Therapeutic Targets for Disorders of the Central Nervous System.. 14
Mobile Wellness Challenge ....................................................................................... 15
AstraZeneca Challenge: Novel Approaches to Form and Particle Control a Crystalline Material ..................................................................................................... 17
Pharmaceutical Distribution and Reimbursement Optimization ................................ 18
March of Dimes General Research Grants ............................................................... 19

Please note that a faculty member’s research administrator will serve as the liaison on all aspects of the internal application process. If you are unsure of whom to talk to, your department contact can be found at the following link. If you pursue any grant opportunity featured in this report, please contact your research administrator first to formulate a submission plan and timeline.

The UMHS Corporate and Foundation Relations team can assist in this process, including providing direct communication with the funding entity to obtain guidance on project appeal/applicability to the funder, provide examples of previously funded UM proposals, and answer general faculty questions.

Grantor: Bloomberg Philanthropies
Grant Opportunity: Program Funding

Keyword: Public Health

Award Amount: $15 million

Deadline: June 1, 2018

Request for Proposals: Bloomberg Initiative to Reduce Tobacco Use STOP (Stop Tobacco Organizations and Products)

https://www.bloomberg.org/program/public-health/stoptobacco/#overview

A competitive application process is open to determine the lead organization(s) for Stopping Tobacco Organizations and Products (STOP). The global tobacco industry watchdog will aggressively monitor deceptive tobacco industry practices to undermine public health.

STOP will support the creation of a robust global monitoring system that complements existing efforts in identifying industry deception. The tobacco industry watchdog will deliver regular reports detailing industry tactics and strategies both at global and country-level and will provide tools and training materials for countries to combat industry influence. STOP will also liaise with existing Bloomberg Initiative to Reduce Tobacco Use partners to supplement country-level grants that assist nonprofits and governments in pushing back strongly against industry’s interference. Findings will be publicly available and fully aligned with Article 5.3 of the World Health Organization’s Framework Convention on Tobacco Control that clearly outlines the prohibition of tobacco industry involvement in government policy making.

STOP will divide resources between robust monitoring and reporting of industry behavior, and combating the false narratives of Big Tobacco on the ground.

Nongovernmental organizations and academic institutions are invited to submit their best and boldest ideas for STOP. Groups may apply jointly (up to three organizations per application) but at least one organization must be from a low- or middle-income country.

Funding: $15 (USD) million over 3 years

Submission date: June 1, 2018, 5PM ET

Grantor: All Nippon Airways

Grant Opportunity: Contest

Keyword: Assistive Technology; Devices & Robotics; Prizes

Award Amount: $10 Million

Deadline: October 31, 2018
Avatar XPRIZE

https://avatar.xprize.org/

Bridging Distance, Time, and Culture for All

Designing avatars for—IMPACT.

We see the potential for avatars to take on many different forms and be used in numerous scenarios. For example:

Providing Care: Avatars could give the experience of your presence and care to anyone instantly, regardless of distance.

Disaster Relief: Avatars could transport critical life-saving skills in real-time to remote, disaster-struck areas where it is too dangerous for humans to go.

Multipurpose Utility: Experts can utilize avatars to provide unique services or rare trade skills for critical maintenance or repairs.

The winning team will combine technologies to demonstrate a robotic avatar that allows an untrained operator to complete a diverse series of tasks, from simple to complex, in a physical environment at least 100km away.

Prize Purse: The $10 million ANA Avatar XPRIZE is a four-year competition focused on accelerating the integration of emerging and exponential technologies into a multipurpose avatar system that will seamlessly transport human skills and experience to the exact location where and when they are needed.

XPRIZE believes that solutions can come from anyone, anywhere. Scientists, engineers, academics, entrepreneurs, and other innovators with new ideas from all over the world are invited to form a team and register to compete.

Registration closes October 31, 2018

Grantor: Cystic Fibrosis Foundation

Grant Opportunity: Research Grants

Keyword: Basic Science; Cystic Fibrosis; Genetic Disorders; Pulmonary and Respiratory; Research Grant

Award Amount: $250,000+

Deadline: May 7, 2018; December 3, 2018

Cystic Fibrosis Foundation Research Grants – Spring Cycle
Research Grants are offered to encourage the development of new information that contributes to the understanding of the basic etiology and pathogenesis of CF. In addition, consideration will be given to those projects that provide insight into the development of information that may contribute to the development of new therapies for CF. All proposals must be hypothesis driven, and sufficient preliminary data must be provided to justify support from the Cystic Fibrosis Foundation. Information derived from such studies will hopefully lead to submission to other funding agencies, such as the National Institutes of Health (NIH).

Research Grant applications must focus on basic science research.

Funding of up to US$125,000 per year, plus eight percent (8%) indirect costs may be requested. Awards may be approved for up to a two-year period. Funding for Year 2 is contingent upon submission and approval of a renewal progress report and the availability of funds.

*Applicants may submit only one research grant application in 2018 (either spring or fall cycle).*

**Deadlines**

Spring cycle applications: May 7, 2018

Fall cycle applications: December 3, 2018

**Grantor:** One Mind

**Grant Opportunity:** Research Grants

**Keyword:** Basic Science; Chronic Diseases; Psychiatric; Research Grant

**Award Amount:** $250,000

**Deadline:** May 15, 2018

**One Mind Rising Star Awards**

[https://onemind.org/guiding-focus/rising-star-awards/](https://onemind.org/guiding-focus/rising-star-awards/)

Identifying and funding critical and groundbreaking brain health research

Given the challenges of understanding and finding therapies for brain illnesses and injuries, the One Mind Rising Star Awards encourage the community of researchers to innovate in their basic and translational science to benefit patients, while supporting the research of emerging leaders in the field.
One Mind, in collaboration with Janssen Research & Development, is offering up to three Rising Star Research Awards: and in collaboration with Inscopix, a Technology Supplement Grant in 2018. The overarching goal is to award promising, early career investigators an opportunity to enhance or accelerate research on major neuropsychiatric disorders, such as anxiety, addiction, bipolar disorder, depression, post traumatic stress, schizophrenia, and traumatic brain injury. Total funding for each of the three Rising Star Awards is $250,000, with $83,333 distributed annually over a 3 year period.

The 2018 Rising Star Awards are:

One Mind / Janssen Rising Star Translational Research Award in Memory of Jeffrey S. Nye, M.D., Ph.D.

One Mind Rising Star Bipolar Disorder Translational Research Award

One Mind Peter Chiarelli Rising Star Collaborative Research Award

One Mind / Inscopix Technology Supplement Grant

One Mind / Janssen Rising Star Translational Research Award in Memory of Jeffrey S. Nye, M.D., Ph.D.

This award is directed toward translational research on neuropsychiatric disorders.

Examples of research within scope include, but are not limited to, studies that aim to:

- Discover biological mechanisms of neuropsychiatric disorder(s);
- Identify or advance biomarker development for neuropsychiatric disorder(s);
- Develop targeted therapies to prevent the onset or progression of neuropsychiatric disorders, mitigate their negative effects on brain function and behavior, or promote recovery;
- Characterize similarities and differences in biological mechanisms between two or more neuropsychiatric disorders; or
- Evaluate the effects of co-morbid conditions on neuropsychiatric disorders.

One Mind Rising Star Bipolar Disorder Translational Research Award

This award is limited to translational research on bipolar disorder.

Examples of research within scope include, but are not limited to, studies that aim to:

- Discover biological mechanisms for bipolar disorder;
- Identify or validate biomarkers of bipolar disorder;
Develop targeted therapies aimed at preventing the onset or progression of bipolar disorder, or therapies aimed at promoting recovery;

Characterize similarities and differences in biological mechanisms between bipolar disorder and one or more neuropsychiatric disorders; and/or

Evaluate the effects of co-morbid conditions on bipolar disorder.

One Mind Peter Chiarelli Rising Star Collaborative Research Award

This award aims to accelerate secondary analysis of large and complex clinical data for hypothesis generation, validation, and/or bi-directional translational research. Collaborative studies with neuropsychiatric research consortia to accelerate the collection, curation, integration and/or analysis of large, complex clinical data are within scope.

Examples of research within scope include, but are not limited to, studies that aim to:

- Validate promising biomarkers or diagnostic tools:
- Identify similarities and differences between two or more neuropsychiatric disorders;
- Understand the effects of co-morbid conditions of neuropsychiatric disorders;
- Compare the effects of treatments on whole or select patient populations; or
- Generate new hypotheses from existing clinical data, and test them in relevant pre-clinical or computational models, or in small pilot clinical studies.

One Mind / Inscopix Technology Supplement Grant

Applicants to any of the three Rising Star Award categories whose proposal can be enhanced by optical interrogation of neural circuit/ensemble dynamics are encouraged to apply for this supplemental award from Inscopix. The supplement for each awardee includes:

- 1 state-of-the-art nVoke miniature microscope system for integrated in vivo Ca+2 imaging and optogenetics (simultaneous or sequential) in the brains of freely behaving mice. Applicants can request an nVista system in lieu of nVoke should their proposal require only Ca+2 imaging either in the mouse brain and/or in the rat neocortex and hippocampus.

- Full scientific support including a dedicated Field Scientific Consultant for the duration of the project to provide on-site training and guidance to the awardees, from experimental design to data analysis. The award will also provide an opportunity to engage with Inscopix’s transdisciplinary team of neuroscientists, data scientists, and engineers.
Full technical support including iCare (no questions asked repair and replacement service, for the duration of the award).

Your completed RFP application must be submitted no later than May 15th, 2018.

Grantor: Myotonic Dystrophy Foundation
Grant Opportunity: Program Funding
Keyword: Chronic Diseases; Drug Discovery & Development; Genetic Disorders; Neurological Disorders; Neuromuscular Disorders; Rare or Orphan Diseases; Research Grant
Award Amount: $200,000
Deadline: May 7, 2018
Request for Proposals: Mouse Drug Testing Facility for Myotonic Dystrophy

http://www.myotonic.org/grant-opportunities-awards

The Myotonic Dystrophy Foundation (MDF) is pleased to announce a Request for Proposals to establish a mouse drug testing facility for myotonic dystrophy type 1 (DM1). MDF intends to support the establishment of a contract-based testing facility by funding activities necessary to set up efficacy testing in the HSA-LR model of DM1 (Mankodi et al., 2000). The facility would then operate under contracts from drug developers and academics to ensure independent and rigorous testing of candidate therapeutics.

This RFP will provide funding to develop a mouse drug testing facility for DM. The successful applicant is expected to establish standard operating procedures for a specified battery of endpoint measures including determination of mean, variability and potentially timecourse. The overall goal is to ensure readiness of a facility to take on drug efficacy testing contracts from pharmaceutical and biotechnology companies and academic drug developers.

Amount: Not to exceed $200,000
Proposals Due: May 7, 2018, 5:00 PM PT

Grantor: Elsa U. Pardee Foundation
Grant Opportunity: Research Grants
Keyword: Cancer; Chronic Diseases; Research Grant
Award Amount: $200,000 (?
Deadlines: April 30, 2018; August 31, 2018
Elsa U. Pardee Foundation Research Grant Program

http://www.pardeefoundation.org/grants.aspx

The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested.

Deadlines: April 30, 2018; August 31, 2018

Grantor: Cystic Fibrosis Foundation

Grant Opportunity: Postdoctoral Fellowships

Keyword: Basic Science; Cystic Fibrosis; Genetic Disorders; Post-Doctoral Fellowship; Pulmonary and Respiratory

Award Amount: $128,550

Deadlines: May 7, 2018; December 3, 2018

Cystic Fibrosis Foundation Postdoctoral Research Fellowship Award

https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Training-Awards/Postdoctoral-Research-Fellowship-Award/

Postdoctoral research fellowships are offered for support of postdoctoral research training related to CF. The applicant must indicate a commitment to CF-related research.

**Applicants may only submit one (1) Postdoctoral Research Fellowship application in 2018**

Awards may be approved for up to a two-year period. Funding for Year 2 is contingent upon submission and approval of a renewal progress report and the availability of funds.

A third year of support may be available as an option to highly qualified candidates and will be considered after completion of 18 months of CFF-supported training.

Deadlines

Spring cycle applications: May 7, 2018

Fall cycle applications: December 3, 2018
Grantor: FSH Society
Grant Opportunity: Research Grants
Keyword: Basic Science; Chronic Diseases; Genetic Disorders; Neuromuscular Disorders; Post-Doctoral Fellowship; Research Grant
Award Amount: $125,000
Deadline: August 31, 2018; February 28, 2019

FSH Society Fellowship and Grants Program

https://www.fshsociety.org/grants/apply-for-a-grant/

The FSH Society offers grants, research fellowships and postdoctoral fellowships to support research relevant to understanding the molecular genetics and cause of Facioscapulohumeral Muscular Dystrophy (FSHD).

The Fellowship and Grants Program

The FSH Society, Inc. (the “Society”) sponsors research programs to meet needs of critical importance in the research of facioscapulohumeral muscular dystrophy ("FSHD").

Each year, the Society will accept requests for research funding. All proposals are subject to peer review to identify the most meritorious and innovative to be funded.

The following programs are available to support research efforts:

A. Research Fellowships--provide support for graduate student researchers at any stage of their research career.

B. Targeted Project Research Grants--provide one-time support for research projects proposed by investigators at any stage of their independent research career.

C. Research Opportunity Grants--provide rapid, one-time funding of novel ideas for finding a solution to urgent problems with immediate human benefit.

The FSH Society awards grants for predoctoral fellowships, postdoctoral fellowships, and research grants to senior investigators. Awards have ranged from $5,000 to $125,000 per year. Strong preference is given to excellent, early-career and early-stage proposals in the range of $30,000-50,000 per year. Smaller and larger awards will be considered. Grants are usually for one year, with the possibility of renewal for up to two additional years, subject to satisfactory progress reports. We expect successful projects to be able to attract future funding from other organizations.

Submission Deadlines: February 28/29 and August 31 of each year.
Grantor: Cystic Fibrosis Foundation
Grant Opportunity: Pilot and Feasibility Awards
Keyword: Basic Science; Cystic Fibrosis; Genetic Disorders; Pulmonary and Respiratory; Research Grant
Award Amount: $100,000+
Deadlines: May 7, 2018; December 3, 2018

Cystic Fibrosis Foundation Pilot and Feasibility Awards – Spring Cycle


Pilot and Feasibility Awards are offered to support projects that will develop and test new hypotheses and/or new methods (or those being applied to the problems of cystic fibrosis for the first time), and to support promising new investigators as they establish themselves in research areas relevant to cystic fibrosis. The intent of these awards is to enable investigators to collect sufficient data to compete successfully for support from the NIH or other funding agencies. Special consideration will be given to those projects that propose innovative and creative approaches to the problems of CF. Applications for continued funding of the same project, or for long-term support of an investigator, will not be considered.

Pilot and Feasibility Award applications must focus on basic science research. Proposals that include methodologies requiring human subjects or sampling of materials from human subjects will be considered under this mechanism only if the sampling method constitutes minimal patient risk (e.g., venipuncture, nasal brushings) and the sample will be utilized in basic or laboratory research.

**Applicants may only submit one (1) Pilot and Feasibility Award application in 2018**

Funding of up to US$50,000 per year, plus eight percent (8%) indirect costs may be requested. Awards may be approved for up to a two-year period.

Deadlines

Spring cycle applications: May 7, 2018

Fall cycle applications: December 3, 2018

Grantor: Aetna Foundation
Grant Opportunity: Program Funding
Keyword: Disparities; Public Health; Under-represented Populations

Award Amount: $100,000

Deadline: April 18, 2018

Aetna Foundation 2018 Cultivating Healthy Communities Grant Program


The Cultivating Healthy Communities (CHC) grant program is geared specifically towards nonprofit organizations that work with underserved, low-income, and minority populations in the contiguous United States. CHC seeks to catalyze measurable improvements in community health outcomes. Our funding directly supports efforts to make underserved communities healthier places to live, work, learn, play and pray. Through this RFP, we invite submissions for projects that address the social determinants of health and participants’ physical, mental, and social well-being.

Cultivating Healthy Communities Domains and Indicators

Built Environment

• Improved walkability, bikeability, and use of public spaces in a community

Community Safety

• Increased collaboration between local law enforcement and community members to proactively address immediate public safety issues, public health issues, or both

Environmental Exposures

• Decreased exposure to air and water contaminants
• Increased understanding, monitoring, and reporting of local environmental hazards by community residents

Healthy Behaviors*

• Increased consumption of fruits and vegetables
• Increased physical activity and stress reduction activities

Social/Economic Factors

• Increased access to healthy foods through the development of new or enhanced retail options, including resident-owned businesses
Applications under this domain are very strongly encouraged to focus on changing local policy. We will prioritize policy-focused projects when selecting sustainable approaches to healthy behaviors.

Applicants can request a total grant award between $50,000 and $100,000 for the entire project period.

We will not accept applications from organizations with Aetna Foundation grants that are still active as of June 30, 2018.

All Stage 1 applications must be received by April 18, 2018 at 3PM ET.

Grantor: AstraZeneca Challenge
Grant Opportunity: Research Competition
Keyword: Infectious Disease; Research Grant; Vaccine
Award Amount: $100,000
Deadline: August 10, 2018

Culture of Select Poultry Viruses in Immortalized Cell Substrates

https://www.innocentive.com/ar/challenge/9933916

Vaccinations are recommended for people of all ages as a means to prevent infectious diseases by helping the body’s defenses mount an immune response to known pathogens. Many vaccines are produced in chicken eggs with a manufacturing process that has been used for decades. Although high yields are reliably produced, this method is time consuming and expensive, requiring a large number of eggs. Therefore, the Seeker desires a novel approach for culturing viruses in immortalized cell substrates.

The Challenge has a special award structure. A solution proven to be viable for more than one virus will be eligible for multiple awards of $100,000 each.

This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and sample delivery.

Overview: The seasonal influenza vaccine is the most recognizable of vaccines that are propagated in chicken eggs. It is developed more than 6 months in advance of the flu season to allow for enough time to scale up adequate quantities of the vaccine. Unfortunately, this lag may be problematic if the selected strains do not match the ones predominantly in circulation during the winter. The investment in the number of chickens to generate the eggs required to produce large batches of vaccine is quite costly. Furthermore, vaccines that are produced in eggs are not suitable for people with egg allergies. Finding an alternative means for making vaccines without chickens is highly attractive not only from a health care perspective, but also in terms of animal
welfare. Therefore, the Seeker desires a novel approach for culturing viruses in immortalized cell substrates.

The Challenge award is contingent upon theoretical evaluation and experimental validation of the submitted solutions by the Seeker.

To receive an award, the Solvers will have to transfer to the Seeker their exclusive intellectual property (IP) rights to the solution. However, the Seeker will be willing to consider a licensing agreement for a partial award if exclusive IP cannot be transferred by the Solver.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 10, 2018.

Grantor: Rivkin Center for Ovarian Cancer

Grant Opportunity: Research Grants

Keyword: Cancer; Chronic Diseases; Ovarian Cancer; Research Grant; Women’s Health

Award Amount: $30,000

Deadline: May 10, 2018

Request for Applications: Rivkin Center for Ovarian Cancer Bridge Funding Award

https://www.rivkin.org/research/apply/

The Rivkin Center for Ovarian Cancer is announcing funds for up to one Bridge Funding Award based on scientific merit. The purpose of Bridge Funding is to allow researchers to produce data needed to substantiate their proposal resubmission to federal funding agencies for a promising new research project. The Rivkin Center provides interim funding of up to $30,000 to researchers who have submitted an R01, R21, K08, K23, or K99 proposal to the National Institutes of Health (NIH) or an original proposal to the Department of Defense (DoD) pertaining to ovarian cancer and who have not received, but were close to, a fundable score. Investigator-initiated projects in all areas of ovarian cancer research are eligible. Special consideration will be given to research that has clinical applicability.

All application materials should be submitted through proposalCENTRAL by the application due date (May 10, 2018, 5PM Eastern Time).

Grantors: American Association for the Advancement of Science and SciLifeLab

Grant Opportunity: Research Prize

Keyword: Basic Science; Career Development; Prizes
Award Amount: $30,000
Deadline: July 15, 2018

Science & SciLifeLab Prize for Young Scientists

http://www.sciencemag.org/science-scilifelab-prize-young-scientists

The Prize is awarded annually to one young scientist for outstanding life science research for which he/she was awarded a doctoral degree in the previous two years. The topic of the entrant's thesis research must be in one of the following categories: Cell and Molecular Biology, Genomics and Proteomics, Ecology and Environment, Translational Medicine. Eligible entrants must have been awarded their doctoral degree in 2015 or 2016. The winners from each category will compete for the grand prize.

Publication: The grand prize-winning essay will be published in Science and essays from the each of the category winners will be published online.

Prize money: US$30,000 for the grand prize winner, US$10,000 for each of the category winners.

Application deadline: July 15, 2018

Grantors: ALS Association, Huntington’s Disease Society of America and Teva

Grant Opportunity: Research Grants

Keyword: Amyotrophic Lateral Sclerosis (ALS); Basic Science; Chronic Diseases; Headache & Migraine; Neurological Disorders; Neuromuscular Disorders; Pain & Palliative Care; Research Grant

Award Amount: $30,000
Deadline: April 29, 2018

TEVA Challenge: Novel Therapeutic Targets for Disorders of the Central Nervous System


Neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and Parkinson’s disease (PD), are becoming an increasing public health concern as the global population ages. Effective treatment options for these debilitating and fatal conditions are severely limited. Although there has been much progress in recent years unraveling disease mechanisms, the underlying causes of these diseases are not well understood. Even in cases where disease-causing mutations have been identified, it is still unclear how they lead to
neuronal death, and ultimately, to the specific cognitive and/or motor deficits associated with each disorder. Migraine, headache disorders and chronic pain are additional areas of unmet need.

The key to discovering effective treatments lies in understanding the basic mechanism or pathophysiology of the condition, thus uncovering new pathways and targets. Successful proposals for this Challenge should focus on novel intracellular or extracellular targets that can be modulated by small molecules or biologics to alleviate the conditions of people suffering from neurodegenerative disorders, including ALS, HD and PD, as well as migraine, headache disorders, or pain.

This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a proposal (maximum of 10 pages, not including references and contact details) to be evaluated by Teva.

The ALS Association and the Huntington’s Disease Society of America (HDSA) are partnering with Teva and co-sponsoring the Challenge awards to seek novel targets with therapeutic potential for ALS and HD, respectively.

The top submissions will be considered for awards ranging from $10,000 to $30,000. Up to $40,000 in cash awards may be distributed. Solvers are NOT eligible for multiple awards. The award has no strings attached; Teva does not request ownership of intellectual property. In addition, if there is mutual interest of the parties, Teva may invite selected Solvers to work out terms for a collaboration contract to further investigate the target. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.

[NOTE: Proposals from Solvers who have the ability to work as a collaboration partner are not required, but are highly encouraged.]

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on April 29, 2018.

Grantor: Johnson & Johnson Innovation
Grant Opportunity: Innovation Competition
Keyword: Assistive Technology; Devices & Robotics; Prizes
Award Amount: $25,000
Deadline: June 1, 2018
Mobile Wellness Challenge


$25,000 + Optional residency at JLABS
The Mobile Wellness Management Challenge - the first in the Health Technology Innovator QuickFire Challenge series - will kick off March 9, 2018 and run through June 1, 2018. Ongoing advances in health technology provide multiple touch points to positively impact patients. Health Technology can be a primary mode of interface, a service offering, or a layer on top of traditional device and/or therapeutic offerings. Wellness and behavioral management applications integrated into mobile and wireless technology are propelling improvements in health outcomes, healthcare services and health research.

Developments in health technology, specifically within mobile, offer the ability to drastically scale improved health care across the globe. Providing better access and care in more places in the world is one of Johnson & Johnson's key commitments in reaching a healthier 2020.

Johnson & Johnson Innovation, JLABS is looking to reward one year of residency at a JLABS location, including mentorship to the individuals or teams who submit the best ideas, technologies, or solutions that are focused around using mobile health technology to advance healthcare. At Johnson & Johnson Innovation, JLABS our goal is to improve the health and wellness of people around the world, and we invite you to join us on this mission!

QuickFire Challenge innovation focus areas:

We are looking for entrepreneurs & innovators with the best ideas, technologies, or solutions across all stages (ideation, pre-clinical, clinical, post-approval) that are using mobile health technology to advance any of these areas:

- Interception and Prevention of Disease
- Intelligent devices for therapy delivery
- Customer collaboration with providers and payers
- Ubiquitous and accessible healthcare

Rewards and benefits

Funding up to $25,000

Residency at an available JLABS location

Acceptance into the HealthTech @ JLABS program

Mentoring & coaching from Johnson & Johnson Innovation experts

Deadline to apply is June 1, 2018

Grantor: AstraZeneca Challenge

Grant Opportunity: Research Competition

Keyword: Basic Science; Pharmaceutical
AstraZeneca Challenge: Novel Approaches to Form and Particle Control a Crystalline Material

https://www.innocentive.com/ar/challenge/9934064

Solids can either be arranged in a repeating three-dimensional crystalline structure or in an amorphous state where there is no regular pattern. The crystalline form affects the solubility and the dissolution rate of a solid, thus the form influences the efficacy of the drug and must be carefully controlled during the manufacturing process. AstraZeneca is seeking collaboration partners who can identify novel technologies or approaches for the large-scale manufacture of a highly complex crystalline pharmaceutical material.

This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.

Overview: To ensure a high level of purity and thermodynamic stability, many active pharmaceutical ingredients are manufactured in a crystalline state. AstraZeneca is looking for a collaborator with whom to develop novel isolation techniques for producing this crystalline pharmaceutical material with limited chemical stability in suitable solvent systems. Successful proposals should focus on novel approaches that will yield the desired crystalline form and particle size (> 20 µm) in a cost-effective manner, under conditions that conform to the Good Manufacturing Practice Regulations at a large-scale in a controlled process.

This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (maximum of 10 pages, including supporting non-confidential information and contact details) to be evaluated by AstraZeneca with a goal of establishing a collaborative partnership. Upon completion of the evaluation, AstraZeneca may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.

[NOTE: Only proposals from Solvers who have the ability to work as a collaboration partner will be considered.]

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on April 16, 2018.

Grantor: AstraZeneca Challenge
Grant Opportunity: Research Competition
In the United States, the current pharmaceutical distribution and reimbursement process is complex having multiple third parties involved in the process. This system is highly regulated to ensure that patients have access to medications that have been tested for safety and efficacy, yet the pricing of these pharmaceuticals as well as the logistics of reimbursement leave much to be desired. The Seeker is looking for innovative ways to deliver more value to the patient and to simplify the process by which patients obtain prescription drugs.

This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.

Overview: The rising cost of prescription medication is of growing concern not only to patients, but also to payers, prescribers, and policy makers. Namely in the United States, the per capita drug spending is the highest in the world. The process by which patients receive pharmaceuticals is complicated and there are many stakeholders. There is a desire to change the pharmaceutical distribution and reimbursement process, something that the e-commerce giant, Amazon, is now attempting. Are there other ways to disrupt this market? The Seeker is looking for innovative ways to deliver more value to the patient by streamlining the process by which patients obtain prescription drugs.

This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (maximum of 10 pages, including supporting non-confidential information and contact details) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.

[NOTE: Only proposals from Solvers who have the ability to work as a collaboration partner will be considered.]

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on April 13, 2018.

Grantor: March of Dimes
Grant Opportunity: Research Grants
Keyword: Basic Science; Disparities; Pediatrics & Child Health; Pulmonary & Respiratory; Research Grant; Vision, Optometry, Ophthalmology

Award Amount: Not Specified

Deadline: May 15, 2018

March of Dimes General Research Grants

https://www.marchofdimes.org/research/research-grants.aspx

March of Dimes now supports research in the following five priorities: Major challenges of premature babies: Necrotizing Enterocolitis, Respiratory Distress Syndrome, and Retinopathy of Prematurity; Biological mechanisms underlying the high incidence of preterm birth in African American women; Genome targeted therapeutics to treat birth defects; Effect of anesthesia in the late fetus or newborn on neurologic development; Preventing and treating chromosomal and structural abnormalities.

Letter of intent due: May 15, 2018